Expanded newborn screening and confirmatory follow-up testing for inborn errors of metabolism detected by tandem mass spectrometry

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 1, 2013, Pages 157-176

  Ozben, Tomris ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Confirmatory follow up testing; Expanded newborn screening; Inborn errors of metabolism; Tandem mass spectrometry

Indexed keywords

ACYLCARNITINE; AMINO ACID; CARBOXYLIC ACID;

AMINO ACID ANALYSIS; BLOOD SAMPLING; DIAGNOSTIC ACCURACY; ELECTROSPRAY; FOLLOW UP; HUMAN; INBORN ERROR OF METABOLISM; LYSOSOME STORAGE DISEASE; MORBIDITY; MORTALITY; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; QUALITY CONTROL; RELIABILITY; REVIEW; TANDEM MASS SPECTROMETRY; URINALYSIS;

FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; METABOLISM, INBORN ERRORS; NEONATAL SCREENING; TANDEM MASS SPECTROMETRY;

EID: 84872982293     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0472     Document Type: Review

References (93)

1. Maternal And Child Health Bureau. Newborn screening: Towards a uniform screening panel and system. Available from: http://mchb.hrsa.gov/programs/ newbornscreening/screeningreportpdf. pdf. 2005. Accessed 26 May, 2012.
2. March of Dimes. Working together for stronger hb. Newborn screening tests. Available from: http://www.marchofdimes. com/baby/bringinghome- recommendedtests.html. 2011. Accessed 26 May, 2012.
3. Dietzen DJ, Rinaldo P, Whitley RJ, Rhead WJ, Hannon WH, Garg UC, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: follow-up testing for metabolic disease identified by expanded newborn screening using tandem mass spectrometry; executive summary. Clin Chem 2009;55:1615-26.
4. Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR. Newborn screening: toward a uniform screening panel and system-executive summary. Pediatrics 2006;117:S296 - 307.
5. ACMG. Newborn screening: toward a uniform screening panel and system. Genet Med 2006;8(Suppl 1):1S-252S.
6. Grosse SD. Does newborn screening save money? The difference between cost-effective and cost-saving interventions. J Pediatr 2005;146:168-70.
7. Grosse SD, Olney RS, Baily MA. The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Policy 2005;4:239-47.
8. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term " cost effective " in medicine. N Engl J Med 1986;314:253-6.
9. Coffield AB, Maciosek MV, McGinnis JM, Harris JR, Caldwell MB, Teutsch SM, et al. Priorities among recommended clinical preventive services. Am J Prev Med 2001;21:1-9.
10. Tran K, Banerjee S, Li H, Noorani HZ, Mensinkai S, Dooley K. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. Clin Biochem 2007;40:235-41.
11. Chen B, Mei J, Kalman L, Shahangian S, Williams I, Gagnon MB, et al. Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders. MMWR 2012;61:1-45.
12. Sweetman L, Millington DS, Therrell BL, Hannon WH, Popovich B, Watson MS, et al. Naming and counting disorders (conditions) included in newborn screening panels. Pediatrics 2006;117:S308 - 14.
13. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
14. Pitt JJ. Newborn screening. Clin Biochem Rev 2010;31:57-68.
15. Lehotay DC, Hall P, Lepage J, Eichhorst JC, Etter ML, Greenberg CR. LC-MS/MS progress in newborn screening. Clin Biochem 2011;44:21-31.
16. Rastogi MV, LaFranchi SH. Congenital hypothyroidism. Orphanet J Rare Dis 2010;5:17.
17. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968;65:281-393.
18. Ross LF. Newborn screening for lysosomal storage diseases: an ethical and policy analysis. J Inherit Metab Dis 2012;35:627-34.
19. Garg U, Dasouki M. Expanded newborn screening of inherited metabolic disorders by tandem mass spectrometry: clinical and laboratory aspects. Clin Biochem 2006;39:315-32.
20. Pollitt RJ. Newborn blood spot screening: new opportunities, old problems. J Inherit Metab Dis 2009;32:395-9.
21. Collins MS, Abbott MA, Wakefield DB, Lapin CD, Drapeau G, Hopfer SM, et al. Improved pulmonary and growth outcomes in cystic fibrosis by newborn screening. Pediatr Pulmonol 2008;43:648-55.
22. Therrell BL Jr., Hannon WH, Hoffman G, Ojodu J, Farrell PM. Immunoreactive trypsinogen (IRT) as a biomarker for cystic fibrosis: challenges in newborn dried blood spot screening. Mol Genet Metab 2012;106:1-6.
23. Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O ' Sullivan BP, et al. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis 2010;33:S255 - 61.
24. Berry GT. Galactosemia: when is it a newborn screening emergency? Mol Genet Metab 2012;106:7-11.
25. Varness TS, Allen DB, Hoffman GL. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. J Pediatr 2005;147:493-8.
26. Rinaldo P, Zafari S, Tortorelli S, Matern D. Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Ment Retard Dev Disabil Res Rev 2006;12:255-61.
27. Kaur G, Srivastav J, Jain S, Chawla D, Chavan BS, Atwal R, et al. Preliminary report on neonatal screening for congenital hypothyroidism, congenital adrenal hyperplasia and glucose-6-phosphate dehydrogenase deficiency: a Chandigarh experience. Indian J Pediatr 2010;77:969-73.
28. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem 2001;47:1945-55.
29. Han M, Jun SH, Song SH, Park KU, Kim JQ, Song J. Use of tandem mass spectrometry for newborn screening of 6 lysosomal storage disorders in a Korean population. Korean J Lab Med 2011;31:250-6.
30. Klein J. Newborn screening from an international perspective - different countries, different approaches. Clin Biochem 2011;44:471-2.
31. Padilla CD, Krotoski D, Therrell BL Jr. Newborn screening progress in developing countries - overcoming internal barriers. Semin Perinatol 2010;34:145-55.
32. Tuncbilek E, Ozguc M. Application of medical genetics in Turkey. Turk J Pediatr 2007;49:353-9.
33. Ozalp I, Coskun T, Tokatli A, Kalkanoglu HS, Dursun A, Tokol S, et al. Newborn PKU screening in Turkey: at present and organization for future. Turk J Pediatr 2001;43:97-101.
34. Yordam N, Ozon A. Neonatal thyroid screening: methods-efficiency- failures. Pediatr Endocrinol Rev 2003;1(Suppl 2):177 - 84; discussion 84.
35. Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S. Hemoglobinopathy control program in Turkey. Community Genet 2006;9:124-6.
36. Tuncbilek E. Clinical outcomes of consanguineous marriages in Turkey. Turk J Pediatr 2001;43:277-9.
37. McCabe LL, McCabe ER. Expanded newborn screening: implications for genomic medicine. Annu Rev Med 2008;59:163-75.
38. Hustace T, Fleisher JM, Sanchez Varela AM, Podda A, Alvarez O. Increased prevalence of false positive hemoglobinopathy newborn screening in premature infants. Pediatr Blood Cancer 2011;57:1039-43.
39. Dhondt JL. Neonatal screening: from the ' Guthrie age ' to the ' genetic age'. J Inherit Metab Dis 2007;30:418-22.
40. Chace DH, Hillman SL, Millington DS, Kahler SG, Roe CR, Naylor EW. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem 1995;41:62-8.
41. Millington DS, Terada N, Chace DH, Chen YT, Ding JH, Kodo N, et al. The role of tandem mass spectrometry in the diagnosis of fatty acid oxidation disorders. Prog Clin Biol Res 1992;375: 339-54.
42. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990;13:321-4.
43. Burlingame AL, Millington DS, Norwood DL, Russell DH. Mass spectrometry. Anal Chem 1990;62:268R-303R.
44. Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106-13.
45. Burgard P, Rupp K, Lindner M, Haege G, Rigter T, Weinreich SS, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2. From screening laboratory results to treatment, follow-up and quality assurance. J Inherit Metab Dis 2012;35:613-25.
46. Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis 2012;35:603-11.
47. Haynes CA, De Jesus VR. Improved analysis of C26:0- lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening. Clin Chim Acta 2012;413:1217-21.
48. Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 2010;33: 521-6.
49. Comeau AM, Hale JE, Pai SY, Bonilla FA, Notarangelo LD, Pasternack MS, et al. Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency. J Inherit Metab Dis 2010;33:S273 - 81.
50. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005;115:391-8.
51. Kaplan M, Hammerman C. Neonatal screening for glucose-6-phosphate dehydrogenase deficiency: biochemical versus genetic technologies. Semin Perinatol 2011;35:155-61.
52. Abduljabbar M, Al Shahri A, Afifi A. Is umbilical cord blood total thyroxin measurement effective in newborn screening for hypothyroidism? J Med Screen 2009;16:119-23.
53. Walter JH, Patterson A, Till J, Besley GT, Fleming G, Henderson MJ. Bloodspot acylcarnitine and amino acid analysis in cord blood samples: efficacy and reference data from a large cohort study. J Inherit Metab Dis 2009;32:95-101.
54. Wilcken B, Wiley V. Newborn screening. Pathology 2008;40:104-15.
55. Auray-Blais C, Cyr D, Drouin R. Quebec neonatal mass urinary screening programme: from micromolecules to macromolecules. J Inherit Metab Dis 2007;30:515-21.
56. la Marca G, Casetta B, Malvagia S, Guerrini R, Zammarchi E. New strategy for the screening of lysosomal storage disorders: the use of the online trapping-and-cleanup liquid chromatography/ mass spectrometry. Anal Chem 2009;81:6113-21.
57. Hoffman GL, Cerda B, Chace DH, Copeland S, Morris MR, Morrissey MA, et al. Newborn screening by tandem mass spectrometry; an approved guideline. I/LA32-A. Wayne PA, USA: Clinical And Laboratory Standards Institute, 2010. Available from: http://www.clsi.org/source/orders/free/ILA32-A.pdf. Accessed 26 May, 2012.
58. Millington DS, Norwood DL, Kodo N, Roe CR, Inoue F. Application of fast atom bombardment with tandem mass spectrometry and liquid chromatography/mass spectrometry to the analysis of acylcarnitines in human urine, blood, and tissue. Anal Biochem 1989;180:331-9.
59. Rashed MS, Bucknall MP, Little D, Awad A, Jacob M, Alamoudi M, et al. Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles. Clin Chem 1997;43:1129-41.
60. Khalid JM, Oerton J, Cortina-Borja M, Andresen BS, Besley G, Dalton RN, et al. Ethnicity of children with homozygous c.985A >?G medium-chain acyl-CoA dehydrogenase deficiency: findings from screening approximately 1.1 million newborn infants. J Med Screen 2008;15:112-7.
61. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 2005;38:296-309.
62. Carpenter KH, Wiley V. Application of tandem mass spectrometry to biochemical genetics and newborn screening. Clin Chim Acta 2002;322:1-10.
63. De Jesus VR, Mei JV, Bell CJ, Hannon WH. Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for Disease Control and Prevention. Semin Perinatol 2010;34:125-33.
64. Miller J, Tuerck J, Chace DH, Copeland S, Rasmussen SA, Rien L, et al. Newborn screening for preterm, low birth weight, and sick newborns; approved guideline. Wayne, PA: Clinical Laboratory Standards Institute; 2009:1 - 69. Available from: http://www.clsi.org/source/orders/free/ILA31-A.pdf. Accessed 30 May, 2012.
65. Wang C, Zhang W, Song F, Liu Z, Liu S. A simple method for the analysis by MS/MS of underivatized amino acids on dry blood spots from newborn screening. Amino Acids 2012;42:1889 - 95.
66. Gallant NM, Leydiker K, Tang H, Feuchtbaum L, Lorey F, Puckett R, et al. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. Mol Genet Metab 2012;106:55-61.
67. Tarini BA, Christakis DA, Welch HG. State newborn screening in the tandem mass spectrometry era: more tests, more falsepositive results. Pediatrics 2006;118:448-56.
68. Lindner M, Ho S, Kolker S, Abdoh G, Hoffmann GF, Burgard P. Newborn screening for methylmalonic acidurias - optimization by statistical parameter combination. J Inherit Metab Dis 2008;31:379-85.
69. Kasper DC, Ratschmann R, Metz TF, Mechtler TP, Moslinger D, Konstantopoulou V, et al. The national Austrian newborn screening program - eight years ' experience with mass spectrometry. Past, present, and future goals. Wien Kiln Wochenschr 2010;122:607-13.
70. Magera MJ, Gunawardena ND, Hahn SH, Tortorelli S, Mitchell GA, Goodman SI, et al. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Mol Genet Metab 2006;88:16-21.
71. Sander J, Janzen N, Peter M, Sander S, Steuerwald U, Holtkamp U, et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 2006;52:482-7.
72. Adam BW, Lim TH, Hall EM, Hannon WH. Preliminary proficiency testing results for succinylacetone in dried blood spots for newborn screening for tyrosinemia type I. Clin Chem 2009;55: 2207-13.
73. Oglesbee D, Sanders KA, Lacey JM, Magera MJ, Casetta B, Strauss KA, et al. Second-tier test for quantification of alloisoleucine and branched-chain amino acids in dried blood spots to improve newborn screening for maple syrup urine disease (MSUD). Clin Chem 2008;54:542-9.
74. Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004 - 2007). J Inherit Metab Dis 2007;30:585-92.
75. Winchester B, Vellodi A, Young E. The molecular basis of lysosomal storage diseases and their treatment. Biochem Soc Trans 2000;28:150-4.
76. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc 1999;281:249-54.
77. Marsden D, Levy H. Newborn screening of lysosomal storage disorders. Clin Chem 2010;56:1071-9.
78. Li Y, Brockmann K, Turecek F, Scott CR, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 2004;50:638-40.
79. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001;308:195-6.
80. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Tay-Sachs and Sandhoff diseases: enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta 2002;318:133-7.
81. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Gaucher and Niemann-Pick diseases - enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newbornscreening cards. Clin Chim Acta 2002;317:191-7.
82. Zhang XK, Elbin CS, Chuang WL, Cooper SK, Marashio CA, Beauregard C, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem 2008;54:1725-8.
83. Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb MH. Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for mucopolysaccharidosis II (Hunter disease). Clin Chem 2007;53:137-40.
84. De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Muhl A, Orsini JJ, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem 2009;55:158-64.
85. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003;49:1797-817.
86. Zhou H, Fernhoff P, Vogt RF. Newborn bloodspot screening for lysosomal storage disorders. J Pediatr 2011;159:7-13 e1.
87. Seashore MR, Seashore CJ. Newborn screening and the pediatric practitioner. Semin Perinatol 2005;29:182-8.
88. Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006;88:307-14.
89. Green NS, Pass KA. Neonatal screening by DNA microarray: spots and chips. Nat Rev Genet 2005;6:147-51.
90. Millington DS, Sista R, Eckhardt A, Rouse J, Bali D, Goldberg R, et al. Digital microfluidics: a future technology in the newborn screening laboratory? Semin Perinatol 2010;34:163-9.
91. Hollegaard MV, Grove J, Thorsen P, Norgaard-Pedersen B, Hougaard DM. High-throughput genotyping on archived dried blood spot samples. Genet Test Mol Biomarkers 2009;13:173-9.
92. Hardin J, Finnell RH, Wong D, Hogan ME, Horovitz J, Shu J, et al. Whole genome microarray analysis, from neonatal blood cards. BMC Genet 2009;10:38.
93. Goldenberg AJ, Sharp RR. The ethical hazards and programmatic challenges of genomic newborn screening. J Am Med Assoc 2012;307:461-2.